Form 4: CytomX Therapeutics CEO Sean McCarthy Reports Acquisition of Shares and Stock Options
SEC Form 4 Filing
CytomX Therapeutics CEO Sean McCarthy reports the acquisition of common stock and stock options, as well as adjustments to his holdings of restricted stock units.
Summary
- On February 4, 2025, Sean A. McCarthy, CEO of CytomX Therapeutics, reported acquiring 180,000 shares of common stock and 195,000 shares of common stock.
- These shares were received as restricted stock units (RSUs) that vest over time.
- McCarthy also acquired options to purchase 800,000 shares and 390,000 shares of common stock, which vest monthly from February 4, 2025, over four years and two years, respectively.
- Following these transactions, McCarthy directly owns 1,032,851 shares of common stock and indirectly owns 93,158 shares through a trust.
- He also holds options to purchase 1,190,000 shares of common stock and 572,500 RSUs.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO increasing their stake in the company is generally a good sign, but it's a routine transaction related to compensation.
Positives
- The CEO's acquisition of shares and options could be interpreted as a positive signal, indicating confidence in the company's future prospects.
Future Outlook
The vesting schedules for the RSUs and stock options indicate a long-term commitment from the CEO to the company's success.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. They are closely watched by investors for signals about management's view of the company's prospects.
Stakeholder Impact
- The CEO's increased ownership could positively influence shareholder confidence.
Key Dates
| Date | Description |
|---|---|
| 02/04/2025 | Date of transaction for common stock and stock option acquisitions. |
| 02/04/2025 | Vesting Commencement Date for stock options. |
| 02/03/2035 | Expiration date for stock options. |
| 02/06/2025 | Date of signature for the Form 4 filing. |
| 03/15/2026 | First vesting date for 1/3rd of the 180,000 RSUs. |
| 03/15/2026 | First vesting date for 50% of the 195,000 RSUs. |
Keywords
CytomX Therapeutics, Sean McCarthy, Form 4, Stock Options, RSUs, Common Stock, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.